Free Trial

Cingulate 8/13/2024 Earnings Report

Cingulate logo
$4.82 +0.06 (+1.26%)
As of 04:00 PM Eastern

Cingulate EPS Results

Actual EPS
-$5.47
Consensus EPS
-$5.64
Beat/Miss
Beat by +$0.17
One Year Ago EPS
N/A

Cingulate Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cingulate Announcement Details

Quarter
Time
Before Market Opens

Conference Call Resources

Cingulate Earnings Headlines

Cingulate (NASDAQ:CING) Upgraded at Roth Capital
Cingulate (NASDAQ:CING) Now Covered by Roth Mkm
Grab This Altcoin Before Trump's Crypto Announcement
Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.
Cingulate Inc Completes Key FDA Study for ADHD Drug
See More Cingulate Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cingulate? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cingulate and other key companies, straight to your email.

About Cingulate

Cingulate (NASDAQ:CING), a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

View Cingulate Profile

More Earnings Resources from MarketBeat